Secondary Logo

Journal Logo

Effects of rolipram, pimobendan and zaprinast on ischaemia-induced dysrhythmias and on ventricular cyclic nucleotide content in the anaesthetized rat

Carceles, M. D.; Aleixandre, F.; Fuente, T.; López-Vidal, J.; Laorden, M. L.*

European Journal of Anaesthesiology (EJA): March 2003 - Volume 20 - Issue 3 - p 205-211
Original Article
Free

Background and objective: This study was designed to compare the haemodynamic, electrophysiological and pharmacodynamic effects of three selective inhibitors of the different isoenzyme forms of phosphodiesterase (PDE) on ischaemia-induced dysrhythmias in the anaesthetized rat. The drugs used were pimobendan, a selective PDE III inhibitor, rolipram, a selective PDE IV inhibitor, and zaprinast, a selective PDE V inhibitor.

Methods: The coronary artery was occluded 15 min after commencing drug administration, and myocardial ischaemia was maintained for 30 min during which the heart rate and mean arterial pressure were recorded. cAMP and cGMP were determined by radioimmunoassay.

Results: Pretreatment with rolipram decreased the duration of ventricular tachycardia without any change in the incidences of dysrhythmias or the mortality rate. This drug did not modify ventricular content of adenosine 3′,5′-cyclic monophosphate (cAMP) or guanosine 3′,5′-cyclic monophosphate (cGMP). Pimobendan (1 mg kg−1 + 0.1 mg kg−1 min) decreased the duration of ventricular tachycardia. This dose of pimobendan and zaprinast (1 mg kg−1 + 0.1 mg kg−1 min−1) increased the incidence rate of ventricular fibrillation following coronary artery ligation and the mortality rate. Moreover, both drugs increased cGMP in the ventricle.

Conclusions: The results demonstrated that pimobendan and zaprinast increased the incidence of dysrhythmias and the mortality rate, which was accompanied by an increase in the ventricular content of cGMP. Rolipram decreased the duration of ventricular tachycardia without a change in the cyclic nucleotide content or in the mortality rate.

University School of Medicine, Departments of *Pharmacology,Anaesthesiology andNuclear Medicine, CSV Arrixaca Hospital, Murcia, Spain

Correspondence to: María Laorden, Departamento de Farmaocología, Facultad de Medicina, E-30100 Murcia, Spain. E-mail: laorden@um.es; Tel: +34 968 367155; Fax: +34 968 364150

Accepted for publication March 2002 EJA 584

The pharmacological treatment of congestive heart failure, a condition associated with a high incidence of ventricular dysrhythmias and sudden cardiac death, is a challenging task for clinicians. Elevated concentrations of adenosine 3′,5′-cyclic monophosphate (cAMP) have been implicated in the genesis of ischaemia-induced dysrhythmias and the lowering of the fibrillation threshold in the dog, pig and baboon heart [1], in the isolated rat heart [2], and in human beings [3]. Direct evidence for the dysrhythmogenicity of cAMP was provided by the decrease in the ventricular fibrillation threshold noted during perfusion of the isolated rat heart by dibutyryl cAMP, the permanent form of cAMP [4]. An infusion of cAMP analogues or agents increasing myocardial cAMP at the visible border of the ischaemic zone in pig hearts can provoke ventricular tachycardia (VT) or ventricular fibrillation [5]. Furthermore, elevation of ventricular guanosine 3′,5′-cyclic monophosphate (cGMP) as well as cAMP increases ischaemia-induced ventricular dysrhythmias in the anaesthetized rat [6,7]. In contrast, it has been suggested that cGMP can be an endogenous intracellular cardioprotector and its actions may account for the low susceptibility to ventricular fibrillation normally encountered in hearts reperfused after sustained ischaemia [8]. On the other hand, it is known that congestive heart failure is associated with a high incidence of dysrhythmias that complicate the management of heart failure and contribute to mortality and morbidity [9]. Numerous treatments have been proposed and tested for the long-term management of chronic heart failure to provide adequate symptomatic relief and protection from sudden death in all patients. Phosphodiesterase (PDE) inhibitors, which raise cAMP content by blocking its hydrolysis, improve the haemodynamic status of heart failure via inotropic or vasodilatory effects, or both, and these drugs have a considerable efficacy in the treatment of congestive heart failure, particularly for inotropic support after cardiac surgery [10,11]. However, chronic administration of these drugs affects survival adversely [12]. In addition, a high dose of milrinone, a selective PDE III inhibitor, increases dysrhythmias during acute myocardial ischaemia in rat [13]. Therefore, the purpose of the present study was to evaluate the effects of different PDE inhibitors on ventricular dysrhythmias and cyclic nucleotide content by use of a model of ischaemia-induced dysrhythmias in the pentobarbital anaesthetized rat. The drugs chosen were pimobendan, a selective PDE III inhibitor, rolipram, a selective PDE IV inhibitor, and zaprinast, a selective PDE V inhibitor.

Back to Top | Article Outline

Methods

Surgical and recording procedures

The animals were cared for in accordance with our Local Ethics Committee and the National Institute of Health Guidelines. The method used to produce coronary artery occlusion in anaesthetized rats has been fully described previously [14]. Briefly, male Sprague-Dawley rats (250-350 g) were anaesthetized with sodium pentobarbital (60 mg kg−1 intraperitoneally). One-hundred-and-forty rats were used in the study. The trachea was cannulated and the animals artificially ventilated with a miniature Ideal® respiration pump (Harvard, Rodent ventilator: 47 breaths min−1, tidal volume 4 mL). The femoral vein was cannulated for drug administration and the carotid artery cannulated for direct measurement of arterial pressure. Mean arterial pressure was calculated as diastolic pressure + one-third pulse pressure. A left thoracotomy was performed and the fourth rib removed. After the pericardium was opened, the heart was exteriorized and a fine silk ligature placed around the left anterior descending coronary artery (the ligature was not tightened at this stage). The heart was then returned to the chest cavity and left to stabilize for 15 min before starting the experimental protocol.

Animals with a mean arterial pressure <70 mmHg after placement of the ligature were excluded from the experiments as were those that demonstrated dysrhythmias before the ligature being tied. Following coronary ligation, animals that died within the first 5 min due to a progressive but complete loss of arterial pressure without demonstrating dysrhythmias were also excluded.

Back to Top | Article Outline

Experimental protocol

After the stabilization period, a drug or physiological saline was administered intravenously (i.v.) as an initial bolus dose followed immediately by a continuous infusion. The three drugs used in this study were given at two different doses: rolipram (30 μg kg−1 + 3 μg kg−1 min−1, or 100 μg kg−1 + 10 μg kg−1 min−1); pimobendan (300 μg kg−1 + 30 μg kg−1 min−1, or 1 mg kg−1 + 0.1 mg kg−1 min−1); and zaprinast (300 μg kg−1 + 30 μg kg−1 min−1, or 1 mg kg−1 + 0.1 mg kg−1 min−1). Control animals were treated only with the appropriated solvents: 25% v/v polyethylene glycol 300 in water, or 10% v/v dimethylsulphoxide in water. The coronary artery was occluded 15 min after commencing drug administration and myocardial ischaemia was maintained for 30 min. Over a 30 min ischaemic period, heart rate and mean arterial pressure were recorded.

To study ventricular cyclic nucleotide content (n = 70), the same protocol described above was followed, with the exception that 30 min following coronary artery ligation the heart was removed. Hearts were rapidly washed in ice-cold saline, the free wall of the left ventricle (ischaemic tissue) and the right ventricle (comprising the right ventricle and the intraventricular septum, non-ischaemic tissue) were frozen and stored at −80°C until the day of assay. The time taken to excise the heart, dissect and freeze was approximately 15 s.

Back to Top | Article Outline

Determination of cyclic nucleotide content

cAMP and cGMP were determined by means of cAMP-3H or cGMP-3H by radioimmunoassay following the indications of the manufacturer (Amersham International, Amersham, UK). Tissues were extracted in 0.3 mol perchloric acid (in a ratio of 1:10 w/v) with a Polytron® homogenizer. Extracts were centrifuged at 12 000 rpm for 15 min using a Biofuge A® centrifuge (Heraus, Berlin, Germany). Supernatant was treated with potassium hydroxide solution until pH 7.5 was reached. The samples were centrifuged once and the supernatant was used for cAMP and cGMP analysis. The sensitivity of the assay for cAMP and cGMP was 2 and 10 pmol mL−1, respectively. Protein was determined according to a Lowry modified procedure [15].

Back to Top | Article Outline

Determination of dysrrhythmias

The number of premature ventricular beats (PVB) and the incidence and duration of VT - a succession of seven or more PVB - and ventricular fibrillation (chaotic ventricular contraction associated with a complete collapse of arterial pressure) were counted 20 min before ligature without drug (control), 15 min before ligature with drug or solvent (−15 min) and during 30 min after the ligature.

Back to Top | Article Outline

Drugs

Rolipram was dissolved in polyethylene glycol. Pimobendan (Boehringer Ingelheim, Spain) and zaprinast (Rhone-Poulenc Rorer, London, UK) were dissolved in dimethylsulphoxide. The drugs were administrated as an i.v. bolus followed by a continuous infusion. Control animals were treated with their respective solvents.

Back to Top | Article Outline

Statistical analysis

All data are the mean ± SD. Data were analysed by one-way analysis of variance followed by the Newman-Keuls post hoc test. The incidence of dysrhythmias was analysed by non-parametric t-test and the observed mortality in drug-treated groups was compared with the corresponding control group by Fisher's exact test.

Back to Top | Article Outline

Results

Effect upon ischaemia-induced dysrhythmias

There were no significant changes in the PVB count and duration of ventricular fibrillation with any of the drugs used compared with controls. Both doses of rolipram did not induce significant changes in the incidence of dysrhythmias or in mortality compared with the control group. In contrast, the incidence of ventricular fibrillation was increased in rats that received higher doses of pimobendan (88%, P < 0.05) or zaprinast (89%, P < 0.05) resulting in an increased in mortality (Fig. 1).

Figure 1

Figure 1

Symbol

Symbol

Symbol

Symbol

Table 1 shows the total PVB count, the duration of VT and ventricular fibrillation in survivors from the 30 min ischaemic period, solvents and the treated groups. Both doses of rolipram and pimobendan (1 mg kg−1 + 0.1 mg kg−1 min−1) significantly (P < 0.05 and <0.01) decreased the duration of VT. However, low-dose pimobendan and both low- and high-dose zaprinast did not significantly affect this variable.

Table 1

Table 1

Back to Top | Article Outline

Haemodynamic effects

Coronary artery occlusion did not induce haemodynamic changes in the rats treated with solvents only. Rolipram and the higher doses of pimobendan did not change the heart rate or arterial pressure. However, the low dose of pimobendan caused significant decreases of heart rate and arterial pressure 10 min after coronary ligature and remained low for 30 min after ligature. Similarly, the high dose of zaprinast decreased heart rate 15 min before coronary artery occlusion and after 20 min after the ligature (Tables 2 and 3).

Table 2

Table 2

Table 3

Table 3

Back to Top | Article Outline

Effect of cyclic nucleotide concentrations

In this series of experiments, significant differences (P < 0.01) in cAMP content were observed between the ischaemic left ventricle and non-ischaemic right ventricle in the groups treated with solvent only (Fig. 2). None of the drugs used had significant effects on the cAMP content in the left or right ventricle (Fig. 2).

Figure 2

Figure 2

On the other hand, significant differences in cGMP content were observed between the ischaemic left ventricle and the non-ischaemic right ventricle in the solvent groups. The higher doses of pimobendan or zaprinast (i.e. 1 mg kg−1 + 0.1 mg kg−1 min−1) increased the cGMP content in the left ventricle (0.031 ± 0.002 pmol mg−1, P < 0.01; 0.027 ± 0.001 pmol mg−1, P < 0.05), respectively, and in the right ventricle (0.076 ± 0.06 pmol mg−1, P < 0.001; 0.047 ± 0.009 pmol mg−1, P < 0.05) compared with the solvent group (Fig. 2).

Back to Top | Article Outline

Discussion

In anaesthetized rats undergoing coronary artery ligation, the PVB count observed at the 30 min postischaemic period was lower than that found by other investigators, although the overall mortality and incidence of dysrhythmias was similar to that previously reported [5,14,16-19]. The cyclic nucleotide concentrations obtained in the present study were similar to those described for the anaesthetized rat [5,13].

The results of the present study indicate the that rolipram inhibitor of Type IV PDE significantly reduced the duration of dysrrhythmias without any changes in the cAMP or cGMP content in the ischaemic left ventricle. In contrast, the high doses of pimobendan or zaprinast exacerbated dysrhythmias during acute myocardial ischaemia. Furthermore, the mortality due to sustained ventricular fibrillation was significantly increased in the groups that received the higher dose of pimobendan or zaprinast. In addition, the high doses of these drugs enhanced the cyclic nucleotide concentrations in this model of ischaemia-induced dysrhythmia. There is evidence to suggest that drug-induced elevations in cyclic nucleotides caused by either selective PDE III inhibition, β-adrenoceptor activation or direct activation of adenylate cyclase are associated with an increased incidence of dysrhythmias [1,3,4,20]. In addition, clinical studies have suggested that PDE III inhibitors such as amrinone and milrinone can have dysrhythmogenic effects during myocardial ischaemia or reperfusion [13,21,23]. Moreover, the higher dose of pimobendan and zaprinast that exacerbated the dysrhythmias increases the cGMP content in the left ventricle, suggesting that cGMP could be implicated in ischaemia-induced dysrhythmias. There is supporting experimental evidence that infusion of cGMP enhances ischaemia-induced dysrhythmias, which raises the possibility of a dysrhythmogenic effect of cGMP in this model [5]. In contrast with the present data, a previous study [19] showed that in the anaesthetized rat, ischaemia-induced dysrhythmias did not modify the cAMP or cGMP content in ischaemic ventricular tissue. In addition, milrinone increased the cAMP content in the left ventricle without changes in the incidence of dysrhythmias, suggesting that cyclic nucleotides are not involved in this model of ischaemia. These differences could be due to the different protocol used. In the previous study, the samples for the subsequent cyclic nucleotide analysis were taken at 15 min or earlier as appropriate. In our study, the samples were taken at 30 min after ligature. In addition, the results obtained with rolipram and zaprinast were in contrast with another study [18] in the anaesthetized rabbit that described an exacerbation of dysrhythmias following myocardial ischaemia and reperfusion with rolipram - whereas zaprinast had no significant effects. These differences may represent an intrinsic difference in excitation-contraction coupling between rat and rabbit myocardium and, therefore, a consequent difference in the effects of PDE inhibitors between species.

With respect to cyclic nucleotide concentrations in dysrhythmogenesis, previous studies in the cat [23], pig [4] and baboon [1] suggest that cAMP concentrations rose in ischaemic tissue and that this rise preceded the onset of fibrillation. However, it has been observed in isolated rat hearts that increases in cAMP occur 30-45 min after ischaemia and that the rise in cAMP was substrate-dependent and inhibited by glucose [4]. It has recently reported that the mechanism by which cAMP is elevated has a profound influence on the fibrillation threshold in isolated rat hearts. Large increases in cAMP caused by forskolin did not cause such a large decrease in the fibrillation threshold as that produced following the smaller increases in cAMP caused by isoprotenolol. Compartmentalization of cAMP may be an explanation for these effects [24]. Unfortunately, research in this area has focused upon the relationship between myocardial cAMP and dysrhythmias, and there is little information about the effect of cGMP and ischaemia-induced dysrhythmias. In this way, it has been shown that cGMP plays an important role in the maintenance and/or genesis of atrial fibrillation [25]. In contrast, it has been suggested that the reduction of the cGMP synthesis increases the susceptibility to reperfusion-induced ventricular fibrillation after sustained ischaemia, suggesting that this nucleotide can be an endogenous intracellular cardioprotector [8].

In conclusion, our results suggest that the administration of the Class III PDE inhibitor pimobendan and the Class V PDE zaprinast are associated with raised myocardial cGMP content in the anaesthetized rat ischaemic left ventricle animal model, whereas the Class IV PDE inhibitor rolipram produces no corresponding rise in cGMP. Both pimobendan and zaprinast administration were associated with an increased mortality from dysrhythmias, an effect not shown with rolipram. We provide evidence that a rise in intracellular cGMP may be important in the aetiology of ischaemia-induced dysrhythmias. However, it is possible that other mechanisms in addition to cyclic nucleotides have been implicated in ischaemiainduced dysrhythmias [26,27].

Back to Top | Article Outline

Acknowledgements

This study was supported by the Fondo de Investigaciones de la Seguridad Social 98/0584, Spain. Rolipram was a gift from Messrs Almirall, C/Cardener, 68-74, E-08024 Barcelona, Spain.

Back to Top | Article Outline

References

1. Podzuweit T. Early arrhythmias resulting from acute myocardial ischaemia; possible role of cyclic AMP. In: Parratt JR, ed. Early Arrhythmias Resulting from Myocardial Ischaemia: Mechanisms and Prevention by Drugs. London, UK: Macmillan, 1982: 171-198.
2. Lubbe WF, Nguyen T, West EJ. Modulation of myocardial cyclic AMP and vulnerability to fibrillation in the rat heart. Fed Proc 1983; 42: 2460-2464.
3. Yoshida Y, Hirai M, Yamada T, et al. Antiarrhythmic efficacy of dipyridamole in treatment of reperfusion arrhythmias: evidence for cAMP-mediated triggered activity as a mechanism responsible for reperfusion arrhythmias. Circulation 2000; 101: 624-630.
4. Lubbe WF, Podzuweit T, Daries PS, Opie LH. The role of cyclic adenosine monophosphate in adrenergic effects on ventricular vulnerability to fibrillation in the isolated perfused rat heart. J Clin Invest 1978; 61: 1260-1269.
5. Podzuweit T, Els DJ, McCarthy J. Cyclic AMP mediated arrhythmias induced in the ischaemic pig heart. Basic Res Cardiol 1981; 76: 443-448.
6. Kane KA, Morcillo-Sanchez EJ, Parratt JR, Rodger IW, Shahid M. The relationship between coronary artery occlusion-induced arrhythmias and myocardial cyclic nucleotide levels in the anaesthetized rat. Br J Pharmacol 1985; 84: 139-145.
7. Packer M. Effect of phophodiesterase inhibitors on survival of patients with chronic congestive heart failure. Am J Cardiol 1989; 63: 41A-45A.
8. Pabla R, Bland-Ward P, Moore PK, Curtis MJ. An endogenous protectant effect of cardiac cyclic GMP against reperfusion-induced ventricular fibrillation in the rat heart. Br J Pharmacol 1995; 116: 2923-2930.
9. Ellison WG, Ellison KE, Sweeney MO, Epstein LM, Maisel WH. Management of arrhythmias in heart failure. Cardiol Rev 2002; 10: 8-14.
10. Pamboukian SV, Carere RG, Webb JG, et al. The use of milrinone in pre-transplant assessment of patients with congestive heart failure and pulmonary hypertension. J Heart Transplant 1999; 18: 367-371.
11. Skrabal MZ, Stading JA, Behmer-Miller KA, Hilleman DE. Advances in the treatment of congestive heart failure: new approaches for an old disease. Pharmacotherapy 2000; 20: 787-792.
12. Movsesian MA. Therapeutic potential of cyclic nucleotide phosphodiesterase inhibitors in heart failure. Expert Opin Investig Drugs 2000; 9: 963-973.
13. Carceles MD, Aleixandre F, Fuente T, López-Vidal J, Laorden ML. Combined phosphodiesterase inhibition and B-blockade in the GI104313, decreases ischemia-induced arrhythmias in the rat. Can J Anaesth 2001; 48: 486-492.
14. Clark C, Foreman MI, Kane KA, McDonald FM, Parrat JR. Coronary artery ligation in anaesthetized rats as a method for the production of experimental dysrrhythmias and for the determination of infarct size. J Pharmacol Meth 1980; 3: 357-358.
15. Hartree EF. Determination of protein: a modification of the Lowry method that gives a linear photometric response. Anal Biochem 1972; 48: 442-446.
16. Marshall RJ, Muir AW, Winslow E. Development of a severe model of early coronary artery ligation-induced dysrrhythmias in the anaesthetized rat. Br J Pharmacol 1981; 73: 951-995.
17. Daugherty A, Frayn KN, Redfern WS, Woodward B. The role of catecholamines in the production of ischaemia-induced ventricular arrhythmias in the rat in vivo and in vitro. Br J Pharmacol 1986; 87: 265-277.
18. Holdbrook M, Coker SJ. Effects of zaprinast and rolipram on platelet aggregation and arrhythmias following myocardial ischaemia and reperfusion in anaesthetized rabbits. Br J Pharmacol 1991; 103: 1973-1979.
19. Jones RB, Frodsham G, Kickinson K, Foster GA. Effect of flosequinam on ischaemia-induced arrhythmias and on ventricular cyclic nucleotide content in the anaesthetized rat. Br J Pharmacol 1993; 108: 1111-1116.
20. Sugiura M, Ogawa K, Yamazaki N. Concentration of myocardial cyclic AMP and ventricular fibrillation induced by aminophyline. Jpn Heart J 1979; 20: 177-182.
21. Colluci WS, Wright RF, Braunwald E. New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. N Engl J Med 1986; 314: 349-358.
22. Lynch JJ, Kitzen JM, Hoff PT, Lucchesi BR. Effects of pimobendan (UD-CG 115 BS) a new positive inotropic molecule on ventricular tachycardia and ischemic ventricular fibrillation in a conscious canine model of recent myocardial infarction. Cardiovasc Pharmacol 1989; 12: 547-554.
23. Corr PB, Witkowski FX, Sobel BE. Mechanisms contributing to malignant dysrrhythmias induced by ischaemia in the cat. J Clin Invest 1978; 61: 109-119.
24. Worthington MG, Opie LH. Contrasting effects of cyclic AMP increase caused by β-adrenergic stimulation or by adenylate cyclase activation on ventricular fibrillation threshold of isolated rat heart. J Cardiovasc Pharmacol 1992; 20: 595-600.
25. Uno T, Kanayama H, Miyazaki Y, Ogawa K, Stake T. Increased cyclic GMP in atrial fibrillation. J Electrocardiol 1986; 19: 51-57.
26. Klein HH, Boble RM, Pich S, Lindert-Heimberg S, Wollenweber J, Nebendahl K. Time delay of cell death by Na+-H+-exchange inhibition in regionally ischemic reperfused porcine hearts. J Cardiovasc Pharmacol 1997; 30: 235-240.
27. Hoag JB, Quian Y-Z, Nayeem MA, D'Angelo M, Kukreja RC. ATP-sensitive potassium channel mediates delayed ischemia protection by heat stress in rabbit heart. Am J Physiol 1997; 273: H2458-H2464.
Keywords:

ENZYME INHIBITORS, phosphodiesterase inhibitors, pimobendan, rolipram, zaprinast; ISCHAEMIA, myocardial ischaemia; NUCLEOTIDES, CYCLIC, cAMP, cGMP; RAT

© 2003 European Society of Anaesthesiology